business
AbbVie’s (ABBV) Allergan Aesthetics Wins FDA Approval for Skinvive by Juvederm
Key takeaways
- Abb Vie’s (ABBV) Allergan Aesthetics Wins FDA Approval for Skinvive by Juvederm Jeff Lewis Mon, June 22, 2026 at 4:21 PM GMT+7 2 min read ABBV Abb Vie Inc.
- 12 High Quality Stocks to Buy for the Long Term.
- On June 16, 2026, Allergan Aesthetics, an Abb Vie Inc.
Abb Vie’s (ABBV) Allergan Aesthetics Wins FDA Approval for Skinvive by Juvederm Jeff Lewis Mon, June 22, 2026 at 4:21 PM GMT+7 2 min read ABBV Abb Vie Inc. (NYSE:ABBV) is one of the
12 High Quality Stocks to Buy for the Long Term.
On June 16, 2026, Allergan Aesthetics, an Abb Vie Inc. (NYSE:ABBV) company, announced the U.S. FDA approval of Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults over the age of 21. Abb Vie said Skinvive by Juvederm is the first and only hyaluronic acid injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop